Revusiran

Summary

Revusiran (CHEMBL4594492) is a phase-3 clinical-stage oligonucleotide; indicated across 1 condition including familial amyloid neuropathy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594492
Name	Revusiran
Type	Oligonucleotide
Max phase	3

Also known as: AD-51547, Revusiran, REVUSIRAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
familial amyloid neuropathy	3	MONDO:0007100	EFO:0004129

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02319005	PHASE3	COMPLETED	ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
NCT02292186	PHASE2	COMPLETED	A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
NCT02595983	PHASE2	COMPLETED	The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).